ROYALTY PHARMA PLC- CL A (RPRX)       41.865  +1.68 (+4.17%)

Company Profile

Royalty Pharma Plc provides drug development services. The company is headquartered in New York City, New York and currently employs 66 full-time employees. The company went IPO on 2020-06-16. The firm collaborate with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products and 10 development-stage product candidates. Those products include AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta. The development-stage product candidates include Aficamten, BCX9930, CPI-0209, Gantenerumab, Omecamtiv mecarbil, Otilimab, Pelabresib, PT027, Seltorexant and Zavegepant. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments, and Royalty Pharma Collection Trust, among others.

Company Info

ROYALTY PHARMA PLC- CL A

110 East 59Th Street

New York City NEW YORK 10022

P: 12128830200.0

CEO: Pablo Legorreta

Employees: 66

Website: https://www.royaltypharma.com